U.S. markets close in 1 hour 58 minutes

Baxter International Inc. (BAX)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
81.40+0.47 (+0.58%)
As of 2:02PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close80.93
Open81.24
Bid81.52 x 800
Ask81.52 x 800
Day's Range81.00 - 81.78
52 Week Range74.79 - 91.45
Volume1,101,059
Avg. Volume2,587,225
Market Cap40.932B
Beta (5Y Monthly)0.68
PE Ratio (TTM)39.32
EPS (TTM)2.07
Earnings DateJul 29, 2021
Forward Dividend & Yield1.12 (1.38%)
Ex-Dividend DateJun 03, 2021
1y Target Est94.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-6% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    Baxter to Host Second-Quarter 2021 Financial Results Conference Call for Investors

    DEERFIELD, Ill., Jun 15, 2021--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its second-quarter 2021 financial results on Thursday, July 29, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/8371319 to pre-register for the call and receive the call information.

  • Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive
    Zacks

    Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive

    Baxter's (BAX) Theranova-enabled HDx therapy is likely to boost clinical outcomes and lower healthcare resource utilization.

  • Baxter Presents Data at 58th ERA-EDTA Congress Indicating Theranova May Reduce Cardiovascular Events and Hospitalizations
    Business Wire

    Baxter Presents Data at 58th ERA-EDTA Congress Indicating Theranova May Reduce Cardiovascular Events and Hospitalizations

    Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today new data showing expanded hemodialysis (HDx) therapy enabled by the Theranova dialyzer may reduce cardiovascular events by 35% and hospitalization rates by 18% according to a new, large, multicenter, retrospective study of Colombian dialysis patients treated with long-term HDx compared to propensity-matched patients treated with High-Flux Hemodialysis.1 The study "Effectiveness of medium cut-off versus high f